Combination Chemotherapy for Relapsed/Refractory Blood Cancers
Phase 2
42
about 10 years
15+
1 site in TX
What this study is about
This trial is testing a combination of chemotherapy drugs to see if it works in people with certain types of blood cancers that have returned or not responded to previous treatment. The treatment includes medications like clofarabine, etoposide, and bortezomib, which work by killing cancer cells or stopping them from growing.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Ofatumumab
- 2.Receive Pegfilgrastim
- 3.Receive Rituximab
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bortezomib, clofarabine, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), dexamethasone, etoposide, ofatumumab, pegfilgrastim, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
injection (Injection), injection, intravenous, infusion, ocular
Primary: Incidence of adverse events, Overall response rate (ORR) (Phase II)
Secondary: Event free survival, Overall survival
Oncology